Are large sample size studies the answer to evaluate effects of drug use in non-clinical trial settings?

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4464-4465

  Yang, Xilin ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE REGULATION; BODY MASS; CANCER RISK; DIABETIC PATIENT; DRUG EFFICACY; DRUG USE; FOLLOW UP; HEART PROTECTION; HUMAN; LETTER; NEOPLASM; PRIORITY JOURNAL; RENAL PROTECTION; SAMPLE SIZE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; NEOPLASMS;

EID: 81755162810     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.9677     Document Type: Letter

References (5)

1. Chang CH, Lin JW, Wu LC, et al.: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. J Clin Oncol 29:3001-3007, 2011
2. Ray WA: Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol 158:915-920, 2003
3. Yang X, Zhao H, Sui Y, et al.: Additive interaction between the reninangiotensin system and lipid metabolism for cancer in type 2 diabetes. Diabetes 58:1518-1525, 2009
4. Yang X, So W, Ko GT, et al.: Independent associations between low-density lipoprotein cholesterol and cancer among patients with type 2 diabetes mellitus. CMAJ 179:427-437, 2008
5. Yang X, So WY, Ma RC, et al.: Predicting values of lipids and white blood cell count for all-site cancer in type 2 diabetes. Endocr Relat Cancer 15:597-607, 2008 (Pubitemid 351880846)